Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: November 13, 2019)

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 



Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment



Complementary and Alternative Medicine

Decision Support

Genetics/Family History


Managing Side Effects

No Travel Required

Predicting Response to Treatment




NEAREST SITE: 2517 miles
University of Pennsylvania Hospital

VISITS: 2 visits over 3 months


NCT ID: NCT01996046

PET/CT to Measure Treatment Response in ER+ Breast Cancer Patients with Bone Mets

18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) for the Evaluation of Response to Therapy in Bone-dominant Metastatic Breast Cancer Scientific Title

To determine whether measuring tumor response to estrogen therapy on a PET/CT scan provides information about treatment response and overall survival.
Who is this for?
Women with estrogen receptor-positive metastatic (stage IV) breast cancer that has spread to the bone and be planning to start a new type of hormone therapy.    Full eligibility criteria
Contact research site

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FDG PET/CT scan, 2 times (at 1 month and 3 months after starting hormonal therapy)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scans are commonly used to look for metastases. </li> <li class="seamTextUnorderedListItem">A small amount of a radioactive drug, or tracer, is used to find cancer cells. </li> <li class="seamTextUnorderedListItem">The most commonly used tracer is called FDG (fluorodeoxyglucose). </li> <li class="seamTextUnorderedListItem">This is why the test is also referred to as an FDG-PET scan.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01996046' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/pet' target='_blank'>Breastcancer.org: PET Scans</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/announcements/using-pet-ct-detection-breast-metastases' target='_blank'>Memorial Sloan Kettering Cancer Center: Using PET/CT in the Detection of Breast Cancer</a> </li></ul>
See more